Bloomberg Law
July 31, 2018, 1:46 PM

Ligand Pharmaceuticals Sued for $3.8 Billion Over Bond Terms (1)

Jef Feeley
Jef Feeley
Bloomberg News

Some Ligand Pharmaceuticals Inc. investors accused the biotech company of unfairly changing the terms of a bond agreement to deny them more than $3.8 billion in payouts.

Eight bond funds that invested in Ligand’s $245 million issuance of 0.75 percent convertible senior notes in 2014 sued the San Diego-based biotech company claiming it changed the trigger for converting the bonds without telling investors.

“The purported amendment would materially and adversely impair the conversion rights of the holders and was not consented to by the holders,’’ the funds, including Citadel Equity Fund and Polygon Convertible Opportunity Master Fund, said in the ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.